Immuno-Biological Laboratories Co Ltd
TSE:4570
Net Margin
Immuno-Biological Laboratories Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | JP |
Market Cap | 4.7B JPY |
Net Margin |
-24%
|
Country | US |
Market Cap | 230.2B USD |
Net Margin |
14%
|
Country | US |
Market Cap | 196.5B USD |
Net Margin |
18%
|
Country | US |
Market Cap | 45.2B USD |
Net Margin |
18%
|
Country | US |
Market Cap | 42.1B USD |
Net Margin |
9%
|
Country | CH |
Market Cap | 38.2B CHF |
Net Margin |
10%
|
Country | KR |
Market Cap | 56.1T KRW |
Net Margin |
23%
|
Country | US |
Market Cap | 32.4B USD |
Net Margin |
21%
|
Country | IE |
Market Cap | 26B USD |
Net Margin |
8%
|
Country | US |
Market Cap | 26B USD |
Net Margin |
19%
|
Country | US |
Market Cap | 21.1B USD |
Net Margin |
21%
|
Profitability Report
View the profitability report to see the full profitability analysis for Immuno-Biological Laboratories Co Ltd.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Immuno-Biological Laboratories Co Ltd's most recent financial statements, the company has Net Margin of -24.5%.